Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference
Viking Therapeutics (NASDAQ: VKTX) announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference from September 4-6, 2024, in New York City. CEO Brian Lian, Ph.D., will be the featured speaker in a fireside chat scheduled for September 4, 2024, from 1:50 – 2:25 p.m. Eastern at the New York Marriott Marquis.
The event will include Dr. Lian's participation in 1-on-1 meetings and a live webcast of the fireside chat. Investors can access the webcast through Viking's website in the Investors & Media section under Webcasts. A replay will be available post-conference. Viking Therapeutics is a clinical-stage biopharmaceutical company focusing on developing novel therapies for metabolic and endocrine disorders.
Viking Therapeutics (NASDAQ: VKTX) ha annunciato la sua partecipazione alla 22ª Conferenza Annuale Globale sulla Salute di Morgan Stanley, che si svolgerà dal 4 al 6 settembre 2024 a New York City. Il CEO Brian Lian, Ph.D., sarà il relatore principale in una chiacchierata informale programmata per il 4 settembre 2024, dalle 13:50 alle 14:25 ora orientale, presso il New York Marriott Marquis.
L'evento comprenderà la partecipazione del Dr. Lian a incontri individuali e una trasmissione in diretta della chiacchierata informale. Gli investitori potranno accedere alla trasmissione sul sito di Viking nella sezione Investitori & Media sotto Webcasts. Una registrazione sarà disponibile dopo la conferenza. Viking Therapeutics è un'azienda biofarmaceutica in fase clinica che si concentra sullo sviluppo di nuove terapie per i disturbi metabolici ed endocrini.
Viking Therapeutics (NASDAQ: VKTX) anunció su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley, que se llevará a cabo del 4 al 6 de septiembre de 2024 en la ciudad de Nueva York. El CEO Brian Lian, Ph.D., será el orador destacado en una charla junto a la chimenea programada para el 4 de septiembre de 2024, de 1:50 a 2:25 p.m. hora del este, en el New York Marriott Marquis.
El evento incluirá la participación del Dr. Lian en reuniones uno a uno y una transmisión en vivo de la charla. Los inversores podrán acceder a la transmisión a través del sitio web de Viking en la sección de Inversores y Medios bajo Webcasts. Una repetición estará disponible después de la conferencia. Viking Therapeutics es una empresa biofarmacéutica en etapa clínica que se centra en desarrollar nuevas terapias para trastornos metabólicos y endocrinos.
Viking Therapeutics (NASDAQ: VKTX)는 2024년 9월 4일부터 6일 사이에 뉴욕에서 열리는 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. CEO Brian Lian, Ph.D.가 2024년 9월 4일 동부시간 오후 1:50부터 2:25까지 예정된 Fireside Chat의 주 연사로 참석할 예정입니다.
이번 행사에는 Dr. Lian의 일대일 미팅과 Fireside Chat의 라이브 웹캐스트가 포함됩니다. 투자자들은 Viking 웹사이트의 투자자 및 미디어 섹션에서 웹캐스트에 접속할 수 있습니다. 컨퍼런스 후에는 재방송도 제공될 예정입니다. Viking Therapeutics는 대사 및 내분비 질환을 위한 새로운 치료법 개발에 집중하는 임상 단계의 생물제약 회사입니다.
Viking Therapeutics (NASDAQ: VKTX) a annoncé sa participation à la 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley, qui se déroulera du 4 au 6 septembre 2024 à New York. Le PDG Brian Lian, Ph.D. sera l'intervenant principal lors d'une conversation au coin du feu prévue pour le 4 septembre 2024, de 13h50 à 14h25 heure de l'Est, au New York Marriott Marquis.
L'événement comprendra la participation du Dr. Lian à des réunions individuelles et une diffusion en direct de la conversation. Les investisseurs peuvent accéder à la diffusion via le site web de Viking dans la section Investisseurs & Médias sous Webcasts. Un replay sera disponible après la conférence. Viking Therapeutics est une entreprise biopharmaceutique en phase clinique qui se concentre sur le développement de nouvelles thérapies pour les troubles métaboliques et endocriniens.
Viking Therapeutics (NASDAQ: VKTX) gab bekannt, dass es an der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley teilnehmen wird, die vom 4. bis 6. September 2024 in New York City stattfindet. Der CEO Brian Lian, Ph.D. wird der Hauptredner bei einem Fireside Chat sein, der für den 4. September 2024 von 13:50 bis 14:25 Uhr Eastern Zeit im New York Marriott Marquis geplant ist.
Die Veranstaltung umfasst die Teilnahme von Dr. Lian an Einzelgesprächen sowie eine Live-Übertragung des Fireside Chats. Investoren können über die Website von Viking im Abschnitt Investoren & Medien unter Webcasts auf die Übertragung zugreifen. Eine Aufzeichnung wird nach der Konferenz verfügbar sein. Viking Therapeutics ist ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung neuartiger Therapien für metabolische und endokrine Störungen konzentriert.
- None.
- None.
Details are as follows:
- Morgan Stanley 22nd Annual Global Healthcare Conference
Details: Dr. Lian will participate in a fireside chat and in 1-on-1 meetings
Conference dates: September 4-6, 2024
Fireside Chat Timing: 1:50 – 2:25 p.m. Eastern on Wednesday, September 4, 2024
Location: New York Marriott Marquis
A live webcast of the fireside chat may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-morgan-stanley-22nd-annual-global-healthcare-conference-302232102.html
SOURCE Viking Therapeutics, Inc.
FAQ
When is Viking Therapeutics (VKTX) participating in the Morgan Stanley Healthcare Conference?
Who will represent Viking Therapeutics (VKTX) at the Morgan Stanley conference?
What type of presentation will Viking Therapeutics (VKTX) give at the Morgan Stanley conference?
Where can investors watch the Viking Therapeutics (VKTX) presentation at the Morgan Stanley conference?
What is the focus of Viking Therapeutics (VKTX) as a company?
